Developer docs
API playgroundTry for free, no card

Search company profiles

Cumulus Neuroscience

Full company profile

uuid0000amw

Namestring
Cumulus Neuroscience
Legal namestring
Cumulus Neuroscience Limited
Company typeenum
Private
Founded yearint
2015
Descriptiontext

Cumulus Neuroscience Limited is a Belfast-headquartered (UK) private digital-health company that develops the NeuLogiq Platform, an integrated multi-modal biomarker system combining a tablet-based cognitive assessment battery, a wireless dry-sensor EEG headset (FDA 510(k) cleared and UKCA marked in 2023), and proprietary machine-learning analytics for CNS clinical trials. The company deploys the platform exclusively for use in biopharma-sponsored clinical studies — Phase 0 through Phase 3 — and does not sell it for individual or standalone in-clinic use; revenue is generated through enterprise clinical-trial contracts supported by an in-house Clinical Operations and Scientific team. Its core customers are global pharmaceutical companies developing CNS therapeutics in Alzheimer's disease, neuropsychiatry, and other neurodegenerative indications, and the platform was co-designed with ten top pharma companies (J&J, Lilly, MSD, Pfizer, Roche, Takeda, Biogen, Boehringer Ingelheim, BMS, GSK) through the Cumulus Pharma Advisory Group (CPAG).

The business operates with offices in Belfast, Dublin, and a Japan clinical operations presence, deploying studies across the UK, US, Europe, Canada, Australia, and Japan. Revenue mechanics are enterprise-direct (multi-year, quote-based trial contracts) with the platform functioning as both a clinical-trial endpoint instrument and a longitudinal real-world data collection system. Beyond the core trial-deployment business, Cumulus is developing AccelADx, an AI-enabled Alzheimer's screening test being validated in the 1,000+ participant Bio-Hermes 2 study, supported by ~£2.2M of Innovate UK grant funding in 2024. The company has raised approximately £9.25M in disclosed equity (2020 seed, £6M in May 2021 led by DDF/LifeArc/UK Future Fund, £3.25M in July 2025 led by Whiterock Finance) and is led by CEO Tina Sampath (ex-Gilead, Pfizer, Blue Earth Diagnostics) with co-founder Brian Murphy, PhD as CSO; the Board is chaired by Ricardo Sáinz Fuertes, MD (Eisai) since January 2026.

Short descriptiontext

Cumulus Neuroscience builds the NeuLogiq Platform — an FDA 510(k)-cleared multi-modal digital biomarker system combining tablet-based cognitive assessments, dry-sensor EEG, and proprietary ML analytics — deployed exclusively into CNS clinical trials for global biopharma sponsors including J&J, Lilly, Pfizer, Roche, Takeda, Biogen, and others.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersBelfast, United Kingdom
HQ citystring
Belfast
HQ countrystring
United Kingdom
HQ regionstring
Europe
Markets served

Serves global market

Offices3 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
CNS clinical trials, digital biomarker platform, EEG brain monitoring, Alzheimer's disease research, neurodegenerative drug development
Industry2 codes
PRIMARYHLAHACAE
Neurological Monitoring (EEG, Seizure/Sleep/Neuro Wearables)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Patient Monitoring, Wearables & Remote Diagnostics
SECONDARYHLACAOAL
Decentralized/Hybrid Trial Enablement (DCT) Platforms
Healthcare & Life Sciences/Digital Health & Health IT/Clinical Trials & Research Informatics (eCOA/ePRO/EDC)
NAICS code2 codes
  • Electromedical and Electrotherapeutic Apparatus Manufacturing334510
  • Other Scientific and Technical Consulting Services54169
SIC code2 codes
  • Electromedical & Electrotherapeutic Apparatus3845
  • Services-Medical Laboratories8071
Product category
CNS Clinical Trial Technology / Digital Biomarker Platform
GTM motion3 records

Each record includes

Type, Description, Source

Revenue model2 records
1CNS Clinical Trial Platform Deployment
TypeProfessional Services
Description

Cumulus Neuroscience deploys the NeuLogiq Platform solely for use in clinical studies — the company does not sell the platform for individual or in-clinic standalone use. Revenue is generated via clinical trial deployments with biopharma sponsors, supported by Clinical Operations and Scientific teams through trial design, deployment, and analysis. Likely structured as project- or study-based fees or multi-study licensing contracts.

cumulusneuro.com
2Recurring / Repeat Study Engagements
TypeSubscription Recurring
Description

The NeuLogiq Platform supports the full clinical development lifecycle from small Phase 0 to large global Phase 3 studies, enabling land-and-expand across multiple studies with the same biopharma sponsor. End-to-end operational, technical, and scientific support drives recurring revenue across trial phases.

cumulusneuro.com
Marketing channels7 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure
Pricing details1 tier
1Quote-based clinical trial deployment, not publicly disclosed
ModelOtherBilling cadenceMulti-year contract
Notes

Pricing not publicly disclosed; tailored to each biopharma sponsor's clinical study requirements; not sold for individual use.

cumulusneuro.com
GTM typeB2B
B2B
Offering typeSoftware
Software
Brand1 of 2 records shown
1NeuLogiq Platform
Description

Cumulus Neuroscience's flagship unified platform integrating tablet-based cognitive assessments, longitudinal EEG, and AI-powered analytics for frequent, reliable in-clinic and at-home monitoring of brain function in CNS clinical trials.

cumulusneuro.com
+1 more record
Core offering1 text field

Cumulus Neuroscience operates the NeuLogiq Platform, an integrated physiological and digital biomarker platform that combines an FDA 510(k)-cleared and UKCA-marked dry-sensor EEG headset, tablet-based cognitive assessments, and AI-powered analytics to deliver frequent, reliable in-clinic and at-home longitudinal monitoring of brain function for CNS clinical trials. The platform is deployed solely for use in clinical studies with biopharma sponsors, supported by in-house Clinical Operations and Scientific teams, and is not sold for individual or standalone in-clinic use. Alongside the platform, Cumulus offers AccelADx, an AI-enabled Alzheimer's screening test being validated in the Bio-Hermes 2 study.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • At-home digital endpoints more sensitive to Alzheimer's disease progression than traditional clinical scales; can reduce trial costs and patient burden while providing earlier efficacy signals
+2 more records
Product overview1 text field

Cumulus Neuroscience offers a single unified platform — the NeuLogiq Platform — composed of four tightly integrated modules: the FDA 510(k)-cleared and UKCA-marked NeuLogiq EEG Headset (hardware), the multi-modal NeuLogiq Assessment Suite (cognition, EEG, mood, speech, sleep), NeuLogiq AI Powered Analytics (proprietary ML/signal processing), and the NeuLogiq Study Management Hub (automated AI-powered dashboards). Together these deliver frequent, reliable in-clinic and at-home longitudinal monitoring of discrete brain functions for CNS clinical trials. Alongside the platform, Cumulus also offers AccelADx, an AI-enabled screening test for early detection of Alzheimer's disease being validated in the Bio-Hermes 2 study. The company deploys the NeuLogiq Platform solely for use in clinical studies with biopharma sponsors; it does not sell the platform for individual or in-clinic use.

Product and service2 records
1NeuLogiq Platform
CategoryCore platform
Description

Unified clinical trial platform combining an FDA 510(k)-cleared and UKCA-marked dry-sensor EEG headset, tablet-based multi-modal cognitive and behavioural assessments, proprietary AI-powered analytics, and an automated Study Management Hub. Deployed by Cumulus solely for use in CNS clinical trials with biopharma sponsors from Phase 0 through Phase 3, in-clinic or at home, across the UK, US, Europe, Australia, Canada, and Japan.

2AccelADx
Scale indicator8 records

Each record includes

Type, Value, Description, Source

Partnership2 partners
1Cumulus Pharma Advisory Group (CPAG)
Strategic tierFlagshipTypeStrategic or Co-development Partner
Description

A working group of 10 top pharma companies (J&J, Lilly, MSD, Pfizer, Roche, Takeda, Biogen, Boehringer Ingelheim, BMS, GSK) that co-designed the NeuLogiq Platform. Formed in 2020, CPAG continues to provide scientific guidance and feasibility-study collaboration.

cumulusneuro.com
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Cumulus is deploying its AccelADx AI-enabled screening test in the Bio-Hermes 2 study, a 1,000+ participant observational study across the US, Canada, and Europe. The Bio-Hermes study is run by GAP and evaluates digital biomarkers against current Alzheimer's diagnostic standards.

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

UK-based digital neuroscience company offering computerized cognitive assessments (CANTAB) and speech-based biomarkers (via Winterlight Labs acquisition) for CNS clinical trials. Directly comparable to Cumulus as a CNS clinical-trial endpoint vendor with biopharma sponsors, though more focused on cognitive testing than EEG hardware.

TypeDirect peer
Description

Australia/US-listed cognitive assessment vendor whose computerized tests are widely used as endpoints in Alzheimer's, depression and other CNS clinical trials. Directly comparable business model of selling validated digital cognitive endpoints into biopharma-sponsored CNS studies.

TypeBroad incumbent
Description

Large clinical-trial technology vendor formed from the merger of Bioclinica, CRF Health and ERT, offering eCOA, imaging, cardiac safety and digital biomarker solutions across therapeutic areas. Comparable to Cumulus in CNS digital endpoints but with substantially broader portfolio, deeper enterprise relationships and larger scale.

TypeBroad incumbent
Description

World's largest CRO with a digital health center of excellence (led by Cumulus board director Robert Ballantine) and growing capabilities in decentralized trials and digital biomarkers. Adjacent incumbent whose eCOA and decentralized trial offerings overlap with NeuLogiq's value proposition at much greater scale.

TypeDirect peer
Description

Digital biomarker company developing wearable sensor-derived endpoints (including some CNS-adjacent measures) for use as clinical trial outcomes. Comparable in providing regulatory-grade digital biomarker endpoints to biopharma sponsors for clinical studies, particularly in CNS and rare disease.

TypeDirect peer
Description

Provider of wearable actigraphy and digital health technology used to capture digital endpoints in clinical research, including CNS studies. Comparable in deploying regulated hardware (FDA-cleared) and analytics software to biopharma sponsors for clinical trial endpoint generation.

TypeEmerging player
Description

Digital health company focused on AI-enabled cognitive assessment and early detection of Alzheimer's and other dementias, with both clinical-trial and consumer-facing products. Comparable to Cumulus in CNS digital biomarker development but with a more consumer/clinic focus rather than pharma trial deployment.

TypeEmerging player
Description

Developer of FDA-cleared wearable biosensors (EpiMonitor, Embrace) and digital biomarkers used in neurology clinical trials and patient monitoring. Comparable in deploying regulated wearable hardware + AI analytics into CNS clinical research, though more focused on seizure/movement disorders.

TypeEmerging player
Description

Speech biomarker company (now part of Cambridge Cognition) developing voice-based digital endpoints for CNS trials in Alzheimer's, Parkinson's and depression. Comparable to Cumulus's language/speech assessment component of NeuLogiq and as a digital endpoint vendor to biopharma sponsors.

TypeBroad incumbent
Description

Major clinical-trial technology platform (Rave EDC, eCOA, decentralized trials, sensor cloud) widely used by biopharma sponsors globally. Comparable as a clinical-trial endpoint and data capture platform, though broader in scope than Cumulus's CNS-focused NeuLogiq offering.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat6 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers12 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability10 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature7 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles10 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance5 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds4 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors8 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Cumulus Neuroscience

CNS Clinical Trial Technology / Digital Biomarker Platformcumulusneuro.com

Cumulus Neuroscience builds the NeuLogiq Platform — an FDA 510(k)-cleared multi-modal digital biomarker system combining tablet-based cognitive assessments, dry-sensor EEG, and proprietary ML analytics — deployed exclusively into CNS clinical trials for global biopharma sponsors including J&J, Lilly, Pfizer, Roche, Takeda, Biogen, and others.

What Cumulus Neuroscience does

Cumulus Neuroscience Limited is a Belfast-headquartered (UK) private digital-health company that develops the NeuLogiq Platform, an integrated multi-modal biomarker system combining a tablet-based cognitive assessment battery, a wireless dry-sensor EEG headset (FDA 510(k) cleared and UKCA marked in 2023), and proprietary machine-learning analytics for CNS clinical trials. The company deploys the platform exclusively for use in biopharma-sponsored clinical studies — Phase 0 through Phase 3 — and does not sell it for individual or standalone in-clinic use; revenue is generated through enterprise clinical-trial contracts supported by an in-house Clinical Operations and Scientific team. Its core customers are global pharmaceutical companies developing CNS therapeutics in Alzheimer's disease, neuropsychiatry, and other neurodegenerative indications, and the platform was co-designed with ten top pharma companies (J&J, Lilly, MSD, Pfizer, Roche, Takeda, Biogen, Boehringer Ingelheim, BMS, GSK) through the Cumulus Pharma Advisory Group (CPAG).

The business operates with offices in Belfast, Dublin, and a Japan clinical operations presence, deploying studies across the UK, US, Europe, Canada, Australia, and Japan. Revenue mechanics are enterprise-direct (multi-year, quote-based trial contracts) with the platform functioning as both a clinical-trial endpoint instrument and a longitudinal real-world data collection system. Beyond the core trial-deployment business, Cumulus is developing AccelADx, an AI-enabled Alzheimer's screening test being validated in the 1,000+ participant Bio-Hermes 2 study, supported by ~£2.2M of Innovate UK grant funding in 2024. The company has raised approximately £9.25M in disclosed equity (2020 seed, £6M in May 2021 led by DDF/LifeArc/UK Future Fund, £3.25M in July 2025 led by Whiterock Finance) and is led by CEO Tina Sampath (ex-Gilead, Pfizer, Blue Earth Diagnostics) with co-founder Brian Murphy, PhD as CSO; the Board is chaired by Ricardo Sáinz Fuertes, MD (Eisai) since January 2026.

Cumulus Neuroscience firmographics

Firmographics
Name
Cumulus Neuroscience
Legal name
Cumulus Neuroscience Limited
Website
https://cumulusneuro.com
Company type
Private
Founded year
2015
Operating status
Operating
Headcount range
11–50 employees
Short description
Cumulus Neuroscience builds the NeuLogiq Platform — an FDA 510(k)-cleared multi-modal digital biomarker system combining tablet-based cognitive assessments, dry-sensor EEG, and proprietary ML analytics — deployed exclusively into CNS clinical trials for global biopharma sponsors including J&J, Lilly, Pfizer, Roche, Takeda, Biogen, and others.
Ownership category
akta.pro rank

Cumulus Neuroscience industry classification

Industry
Product category
CNS Clinical Trial Technology / Digital Biomarker Platform
NAICS
Electromedical and Electrotherapeutic Apparatus Manufacturing (334510), Other Scientific and Technical Consulting Services (54169)
SIC
Electromedical & Electrotherapeutic Apparatus (3845), Services-Medical Laboratories (8071)
akta.pro industry
PRIMARYHLAHACAE
Neurological Monitoring (EEG, Seizure/Sleep/Neuro Wearables)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Patient Monitoring, Wearables & Remote Diagnostics
SECONDARYHLACAOAL
Decentralized/Hybrid Trial Enablement (DCT) Platforms
Healthcare & Life Sciences/Digital Health & Health IT/Clinical Trials & Research Informatics (eCOA/ePRO/EDC)

Keywords

  • CNS clinical trials
  • Digital biomarker platform
  • EEG brain monitoring
  • Alzheimer's disease research
  • Neurodegenerative drug development

Where Cumulus Neuroscience is headquartered

Location

Headquarters

HQ city
Belfast
HQ country
United Kingdom
HQ region
Europe

Offices3 records

Markets served

Cumulus Neuroscience business model

Business model
GTM type
B2B
Offering type
Software
Cost components
Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure

Revenue model

  1. CNS Clinical Trial Platform Deployment: Cumulus Neuroscience deploys the NeuLogiq Platform solely for use in clinical studies — the company does not sell the platform for individual or in-clinic standalone use. Revenue is generated via clinical trial deployments with biopharma sponsors, supported by Clinical Operations and Scientific teams through trial design, deployment, and analysis. Likely structured as project- or study-based fees or multi-study licensing contracts.
  2. Recurring / Repeat Study Engagements: The NeuLogiq Platform supports the full clinical development lifecycle from small Phase 0 to large global Phase 3 studies, enabling land-and-expand across multiple studies with the same biopharma sponsor. End-to-end operational, technical, and scientific support drives recurring revenue across trial phases.

Pricing tiers

ModelBillingPrice
OtherMulti-year contractQuote-based clinical trial deployment, not publicly disclosed

Go-to-market motion3 records

Distribution channels3 records

Marketing channels7 records

Cumulus Neuroscience product offering

Product offering

Core offering

Cumulus Neuroscience operates the NeuLogiq Platform, an integrated physiological and digital biomarker platform that combines an FDA 510(k)-cleared and UKCA-marked dry-sensor EEG headset, tablet-based cognitive assessments, and AI-powered analytics to deliver frequent, reliable in-clinic and at-home longitudinal monitoring of brain function for CNS clinical trials. The platform is deployed solely for use in clinical studies with biopharma sponsors, supported by in-house Clinical Operations and Scientific teams, and is not sold for individual or standalone in-clinic use. Alongside the platform, Cumulus offers AccelADx, an AI-enabled Alzheimer's screening test being validated in the Bio-Hermes 2 study.

Product overview

Cumulus Neuroscience offers a single unified platform — the NeuLogiq Platform — composed of four tightly integrated modules: the FDA 510(k)-cleared and UKCA-marked NeuLogiq EEG Headset (hardware), the multi-modal NeuLogiq Assessment Suite (cognition, EEG, mood, speech, sleep), NeuLogiq AI Powered Analytics (proprietary ML/signal processing), and the NeuLogiq Study Management Hub (automated AI-powered dashboards). Together these deliver frequent, reliable in-clinic and at-home longitudinal monitoring of discrete brain functions for CNS clinical trials. Alongside the platform, Cumulus also offers AccelADx, an AI-enabled screening test for early detection of Alzheimer's disease being validated in the Bio-Hermes 2 study. The company deploys the NeuLogiq Platform solely for use in clinical studies with biopharma sponsors; it does not sell the platform for individual or in-clinic use.

Differentiator

Problem solved

Functional benefit

Brands

  • NeuLogiq Platform: Cumulus Neuroscience's flagship unified platform integrating tablet-based cognitive assessments, longitudinal EEG, and AI-powered analytics for frequent, reliable in-clinic and at-home monitoring of brain function in CNS clinical trials.
  • AccelADx

Products and services

  • NeuLogiq Platform Unified clinical trial platform combining an FDA 510(k)-cleared and UKCA-marked dry-sensor EEG headset, tablet-based multi-modal cognitive and behavioural assessments, proprietary AI-powered analytics, and an automated Study Management Hub. Deployed by Cumulus solely for use in CNS clinical trials with biopharma sponsors from Phase 0 through Phase 3, in-clinic or at home, across the UK, US, Europe, Australia, Canada, and Japan.
  • AccelADx

Quantifiable outcome

  • At-home digital endpoints more sensitive to Alzheimer's disease progression than traditional clinical scales; can reduce trial costs and patient burden while providing earlier efficacy signals
  • +2 more outcomes

Companies that use Cumulus Neuroscience

Customer profile

Named customers12 records

Segments3 records

Ideal customer profiles3 records

Cumulus Neuroscience technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability10 records

Feature7 records

Cumulus Neuroscience partnerships and signals

Strategic signal

Partnerships

Two partnerships are on record, tiered flagship and core.

  • Cumulus Pharma Advisory Group (CPAG)flagshipStrategic or Co-development PartnerA working group of 10 top pharma companies (J&J, Lilly, MSD, Pfizer, Roche, Takeda, Biogen, Boehringer Ingelheim, BMS, GSK) that co-designed the NeuLogiq Platform. Formed in 2020, CPAG continues to provide scientific guidance and feasibility-study collaboration.
  • Global Alzheimer's Platform Foundation (GAP)coreStrategic or Co-development PartnerCumulus is deploying its AccelADx AI-enabled screening test in the Bio-Hermes 2 study, a 1,000+ participant observational study across the US, Canada, and Europe. The Bio-Hermes study is run by GAP and evaluates digital biomarkers against current Alzheimer's diagnostic standards.

Scale indicators8 records

Recent moves7 records

Expansion highlights6 records

Cumulus Neuroscience competitors and assessment

Company assessment

Direct peers

  • Cambridge Cognition: UK-based digital neuroscience company offering computerized cognitive assessments (CANTAB) and speech-based biomarkers (via Winterlight Labs acquisition) for CNS clinical trials. Directly comparable to Cumulus as a CNS clinical-trial endpoint vendor with biopharma sponsors, though more focused on cognitive testing than EEG hardware.
  • Cogstate: Australia/US-listed cognitive assessment vendor whose computerized tests are widely used as endpoints in Alzheimer's, depression and other CNS clinical trials. Directly comparable business model of selling validated digital cognitive endpoints into biopharma-sponsored CNS studies.
  • VivoSense: Digital biomarker company developing wearable sensor-derived endpoints (including some CNS-adjacent measures) for use as clinical trial outcomes. Comparable in providing regulatory-grade digital biomarker endpoints to biopharma sponsors for clinical studies, particularly in CNS and rare disease.
  • ActiGraph: Provider of wearable actigraphy and digital health technology used to capture digital endpoints in clinical research, including CNS studies. Comparable in deploying regulated hardware (FDA-cleared) and analytics software to biopharma sponsors for clinical trial endpoint generation.

Broad incumbents

  • Clario: Large clinical-trial technology vendor formed from the merger of Bioclinica, CRF Health and ERT, offering eCOA, imaging, cardiac safety and digital biomarker solutions across therapeutic areas. Comparable to Cumulus in CNS digital endpoints but with substantially broader portfolio, deeper enterprise relationships and larger scale.
  • IQVIA: World's largest CRO with a digital health center of excellence (led by Cumulus board director Robert Ballantine) and growing capabilities in decentralized trials and digital biomarkers. Adjacent incumbent whose eCOA and decentralized trial offerings overlap with NeuLogiq's value proposition at much greater scale.
  • Medidata (Dassault Systèmes): Major clinical-trial technology platform (Rave EDC, eCOA, decentralized trials, sensor cloud) widely used by biopharma sponsors globally. Comparable as a clinical-trial endpoint and data capture platform, though broader in scope than Cumulus's CNS-focused NeuLogiq offering.

Emerging players

  • Linus Health: Digital health company focused on AI-enabled cognitive assessment and early detection of Alzheimer's and other dementias, with both clinical-trial and consumer-facing products. Comparable to Cumulus in CNS digital biomarker development but with a more consumer/clinic focus rather than pharma trial deployment.
  • Empatica: Developer of FDA-cleared wearable biosensors (EpiMonitor, Embrace) and digital biomarkers used in neurology clinical trials and patient monitoring. Comparable in deploying regulated wearable hardware + AI analytics into CNS clinical research, though more focused on seizure/movement disorders.
  • Winterlight Labs: Speech biomarker company (now part of Cambridge Cognition) developing voice-based digital endpoints for CNS trials in Alzheimer's, Parkinson's and depression. Comparable to Cumulus's language/speech assessment component of NeuLogiq and as a digital endpoint vendor to biopharma sponsors.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

Cumulus Neuroscience social profiles

Digital presence

Cumulus Neuroscience compliance and trust

Trust signal

Compliance5 records

Cumulus Neuroscience financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Cumulus Neuroscience leadership team

Management profile

Number of profiles

Profiles10 records

Cumulus Neuroscience funding detail

Funding detail

Funding overview

Funding rounds4 records

Investors8 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Cumulus Neuroscience M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Cumulus Neuroscience

What does Cumulus Neuroscience do?

Cumulus Neuroscience operates the NeuLogiq Platform, an integrated physiological and digital biomarker platform that combines an FDA 510(k)-cleared and UKCA-marked dry-sensor EEG headset, tablet-based cognitive assessments, and AI-powered analytics to deliver frequent, reliable in-clinic and at-home longitudinal monitoring of brain function for CNS clinical trials. The platform is deployed solely for use in clinical studies with biopharma sponsors, supported by in-house Clinical Operations and Scientific teams, and is not sold for individual or standalone in-clinic use. Alongside the platform, Cumulus offers AccelADx, an AI-enabled Alzheimer's screening test being validated in the Bio-Hermes 2 study.

Is Cumulus Neuroscience a public or private company?

Cumulus Neuroscience is a private company. It is classified as venture growth investor backed and is currently operating.

When was Cumulus Neuroscience founded?

Cumulus Neuroscience was founded in 2015. It employs 11 to 50 people.

Where is Cumulus Neuroscience based?

Cumulus Neuroscience is headquartered in Belfast, United Kingdom, in the Europe region.

How does Cumulus Neuroscience make money?

Two revenue lines are on record. CNS Clinical Trial Platform Deployment is the primary driver. The others are recurring / Repeat Study Engagements.

Who are Cumulus Neuroscience's main competitors?

Direct peers on record are Cambridge Cognition, Cogstate, VivoSense and ActiGraph. Broad incumbents are Clario, IQVIA and Medidata (Dassault Systèmes). Emerging players are Linus Health, Empatica and Winterlight Labs.

Does Cumulus Neuroscience have an API?

No public API is recorded for Cumulus Neuroscience.

What industry is Cumulus Neuroscience in?

Cumulus Neuroscience's product category is CNS Clinical Trial Technology / Digital Biomarker Platform. Its primary akta.pro industry code is HLAHACAE, Neurological Monitoring (EEG, Seizure/Sleep/Neuro Wearables), with a secondary code of HLACAOAL, Decentralized/Hybrid Trial Enablement (DCT) Platforms. Its NAICS code is 334510 and its SIC code is 3845.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Financial PostCumulus Neuroscience and Transpharmation Partner to Carry Objective EEG Measurement from Preclinical Research into First-in-Human StudiesCumulus Neuroscience and Transpharmation announced a partnership to carry objective EEG measurement from preclinical research into first-in-human studies. The collaboration builds on preclinical ketamine and psilocybin datasets showing consistent EEG fingerprints across species, and aims to align preclinical and clinical measurement endpoints. The NeuLogiq platform enables in-clinic and remote monitoring for Phase 1 and beyond.PR NewswireCumulus Neuroscience and Transpharmation Partner to Carry Objective EEG Measurement from Preclinical Research into First-in-Human StudiesCumulus Neuroscience and Transpharmation announced a partnership to align quantitative EEG endpoints from preclinical models to first-in-human studies. The collaboration aims to bridge the measurement discontinuity at the species boundary, with a cross-species ketamine EEG signature demonstrated in mouse, rat, dog, and human. The companies will jointly advise sponsors on EEG paradigms for preclinical and clinical trials.Longevity.TechnologyCumulus Neuroscience presents positive trial data for remote brain monitoring platformCumulus Neuroscience presented three posters at ISCTM 2026 in Philadelphia, including two with a top-20 pharma and academic partners. Interim data showed high adherence and usability for remote brain monitoring in borderline personality disorder and therapy-resistant depression, and a two-minute digital cognitive task matched clinical benchmarks for Alzheimer's trial pre-enrichment.PR NewswireCumulus Neuroscience Presents Data at the ISCTM 2026 Autumn ConferenceCumulus Neuroscience presented three posters at ISCTM 2026, reporting interim data on remote brain monitoring in borderline personality disorder and therapy-resistant depression, and a two-minute cognitive task for Alzheimer's pre-enrichment. The data showed high adherence and usability, supporting shorter, less burdensome CNS trials.Longevity.TechnologyCumulus’ at-home EEG headset clears usability test in ALSCumulus Neuroscience's CNS-102 study found its at-home EEG headset usable by ALS and FTD patients, with 82% of ALS participants rating it easy to use. The platform detected early speech and facial-expression changes missed by clinic testing. The findings support continuous home monitoring for neurodegenerative disease.Longevity.TechnologyCumulus Neuroscience study validates at-home brain health monitorCumulus Neuroscience published final results from its CNS-102 study in Scientific Reports, validating the feasibility and usability of its at-home NeuLogiq brain health monitor for patients with ALS and frontotemporal dementia. The platform, combining an EEG headset with cognitive tasks, received high usability ratings from participants over an eight-month protocol. The study, conducted with the PRECISIONALS initiative, identified exploratory longitudinal signals in speech fluency and emotion recognition that were not detected by traditional in-clinic assessments.PR NewswireCumulus Neuroscience annonce la publication d'un article dans Scientific Reports démontrant que la plateforme NeuLogiq® est viable et utilisable pour l'évaluation cognitive multimodale à domicile chezCumulus Neuroscience announced the publication of final results from its CNS-102 study in Scientific Reports, demonstrating that its NeuLogiq® home-based platform is viable for multimodal cognitive assessment in patients with ALS and frontotemporal dementia. The study found that 82% of ALS participants rated the platform as easy to use and 75% viewed it positively, validating its ability to collect high-quality longitudinal data comparable to clinical settings.PR NewswireCumulus Neuroscience gibt die Veröffentlichung eines Artikels in der Fachzeitschrift „Scientific Reports" bekannt, der belegt, dass die NeuLogiq®-Plattform für die multimodale kognitive Beurteilung voCumulus Neuroscience announced the publication of final results from its CNS-102 study in Scientific Reports, demonstrating that its NeuLogiq home-use platform is feasible and well-tolerated by patients with ALS and FTD. The study found that 82% of ALS participants rated the platform as user-friendly and 75% viewed the technology positively, while longitudinal data revealed cognitive changes detectable via home monitoring that clinical assessments missed. This development addresses a critical measurement gap in neurodegenerative disease research by combining at-home EEG with multimodal cognitive testing.PR NewswireCumulus Neuroscience Announces Publication in Scientific Reports Demonstrating the NeuLogiq® Platform Is Feasible and Usable for At-Home, Multimodal Cognitive Assessment in People Living with ALS andCumulus Neuroscience announced the publication of final results from its CNS-102 study in Scientific Reports, demonstrating that its at-home NeuLogiq® Platform is feasible and usable for multimodal cognitive assessment in patients with ALS. The study found that 82% of ALS participants rated the platform easy to use and 75% held a positive opinion of the technology, validating its potential to capture cognitive data outside clinical settings. This development addresses a measurement gap in neurodegenerative disease trials by combining EEG with multi-domain cognitive tasks.PR NewswireCumulus Neuroscience Announces Publication in Scientific Reports Demonstrating the NeuLogiq® Platform Is Feasible and Usable for At-Home, Multimodal Cognitive Assessment in People Living with ALS andCumulus Neuroscience announced the publication of final results from its CNS-102 study in Scientific Reports, demonstrating that its at-home NeuLogiq® Platform is feasible and usable for multimodal cognitive assessment in patients with ALS. The study found that 82% of ALS participants rated the platform easy to use, highlighting its potential to capture cognitive changes missed by traditional clinic-based motor-focused endpoints. This peer-reviewed milestone supports the platform's utility for future clinical trials developed in collaboration with major pharmaceutical partners.